NCT04577612已完成2 期
A Randomized Controlled Test of the Effects of CHI-554 on Fear (F-01)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 84
- 试验地点
- 1
- 主要终点
- Fear ratings
研究概览
简要总结
This is a randomized, double-blind, placebo-controlled phase 2b clinical trial examining the effects of CHI-554 (CBD) on Fear (F-01)
详细描述
This study will examine the potential of a novel formulation of hemp-derived CBD (CHI-554) to reduce fear elicited via a safe, well-established, controlled, laboratory-based carbon dioxide (CO2)-enriched air biological challenge that causes abrupt increases in bodily arousal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
盲法说明
This is a double-blind study. Investigators, study personnel, and participants will be blinded to the group assignment during the study
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Person is between 18 and 55-years-old (inclusive).
- •Person has a BMI between 18 and 35 kg/m2 (inclusive).
- •Person is willing and able to provide informed consent and attend a 3.5-hour, in-person session.
- •Woman of childbearing potential must not be pregnant or currently breastfeeding.
- •If person uses medication, the person has maintained a stable dose and regimen on existing medications for at least 30 days prior to participation in the study and throughout the study.
- •Person agrees to abide by all study restrictions and comply with all study procedures.
排除标准
- •Person has a known history of significant allergic condition, significant hypersensitivity to the IP, or allergic reaction to cannabis, cannabinoid medications, hemp products, or excipients of the IP.
- •Person has been exposed to any investigational drug or device < 30 days prior to screening or plans to take an investigational drug in the near future (within 30 days).
- •Person has used cannabis, synthetic cannabinoid or cannabinoid analogue (e.g., dronabinol, nabilone), synthetic cannabinoid receptor agonist (e.g., spice, K2), or any CBD- or delta-9- tetrahydrocannabinol (THC)-containing product within 30 days of screening or during the study.
- •Person is currently prescribed medications with likely THC- or CBD- interactions (e.g., warfarin, clobazam, valproic acid, phenobarbital, mechanistic target of rapamycin [mTOR] inhibitors, oral tacrolimus, St. John's wort; Epidiolex).
- •Person is currently prescribed and using a medication used in the treatment of anxiety disorders (e.g., selective serotonin uptake inhibitors, venlafaxine, buspirone, benzodiazepines, hydroxyzine, tiagabine, gabapentin, valproate, lamotrigine, topiramate, beta blockers, clonidine, guanfacine, atypical antipsychotics);
- •Person has a positive drug screen for THC, barbiturates, amphetamines, benzodiazepines, and/or opiates at baseline assessment.
- •Person meets diagnostic criteria for a current DSM-5 diagnosis indexed via the MINI.
- •Person meets criteria for a lifetime history of an unexpected or unprovoked panic attack indexed via the MINI.
- •Person endorses current suicidal intent as indexed via the C-SSRS.
- •Person reports a history of being diagnosed with a respiratory or lung disease (including asthma attacks), cardiac or pulmonary disease, epilepsy, narcolepsy, sleep apnea, anemia, or renal disease during a medical history interview.
- •Person has participated in a study that used a CO2-enriched air procedure.
- •Person has received formal training to tolerate elevated levels of CO2 or bodily arousal (such as free diver training or interoceptive exposure-based treatment).
- •Any other clinically significant disease or disorder or abnormal findings during screening or the baseline assessment that, in the opinion of the investigator, may either put the person at risk because of participation in the study, may confound the results of the study, or affect the person's ability to participate in the study.
- •Person has an acute or progressive disease that is likely to interfere with the objectives of the study, or the ability to adhere to protocol requirements.
- •Woman of childbearing potential, unless she has not engaged in vaginal intercourse or she has used effective contraception when doing so (for example, oral contraception, double barrier, intra-uterine device) for at least 30 days prior to the study.
- •Woman of childbearing potential, unless willing to ensure that she or her partner use effective contraception (for example, oral contraception, double barrier, intra-uterine device) during the study and for 30 days thereafter (however, a male condom should not be used in conjunction with a female condom).
- •Man whose partner is of childbearing potential, unless willing to ensure that he or his partner use effective contraception (for example, oral contraception, double barrier, intra-uterine device) during the study and for 30 days thereafter (however, a male condom should not be used in conjunction with a female condom).
- •Person has history of diagnosis related to hepatic function and/or significantly impaired hepatic function (alanine aminotransferase [ALT] >5 ´ upper limit of normal [ULN] or total bilirubin [TBL] >2 ´ ULN) OR the ALT or aspartate aminotransferase (AST) >3 ´ ULN and TBL >2 ´ ULN (or international normalized ratio [INR] >1.5).
- •Person demonstrates behavior indicating unreliability or inability to comply with the requirements of the protocol.
研究组 & 干预措施
Group 1
Experimental
150 mg CBD
干预措施: CHI-554 (Drug)
Group 2
Experimental
300 mg CBD
干预措施: CHI-554 (Drug)
Group 3
Experimental
600 mg CBD
干预措施: CHI-554 (Drug)
Group 4
Placebo Comparator
Placebo MCT oil
干预措施: CHI-554 (Drug)
结局指标
主要结局
Fear ratings
时间窗: 1 day
Mean mid-challenge fear ratings measured (via continuous transducer input with a range of 1 to 10, where higher ratings reflect more fear) during seconds 300-330 of the experimental procedure (seconds 150-180 of the biological challenge).
次要结局
- AUC in state anxiety ratings(1 day)
- Mean intensity using DSQ(1 day)
- AUC in mean fear ratings(1 day)
- Self-reported anxiety(1 day)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic KeratosisActinic KeratosisNCT02799030Biofrontera Bioscience GmbH105
已完成
2 期
Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIVCovid19NCT05005156Fundación Huésped155
已完成
2 期
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 VaccineCOVID-19 PandemicNCT05652543Sinocelltech Ltd.518
已完成
2 期
To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease DementiaParkinson's Disease DementiaNCT03413384BrainX Corporation100
撤回
2 期
Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA TrialMetabolic DiseaseEndothelial DysfunctionNCT02587572Longeveron Inc.